272 related articles for article (PubMed ID: 32652830)
1. Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-X
Saleh T; Carpenter VJ; Tyutyunyk-Massey L; Murray G; Leverson JD; Souers AJ; Alotaibi MR; Faber AC; Reed J; Harada H; Gewirtz DA
Mol Oncol; 2020 Oct; 14(10):2504-2519. PubMed ID: 32652830
[TBL] [Abstract][Full Text] [Related]
2. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
[TBL] [Abstract][Full Text] [Related]
6. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
9. Senolysis of gemcitabine-induced senescent human pancreatic cancer cells.
Hoque MM; Iida Y; Kotani H; Harada M
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2075. PubMed ID: 38662379
[TBL] [Abstract][Full Text] [Related]
10. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice.
Pan J; Li D; Xu Y; Zhang J; Wang Y; Chen M; Lin S; Huang L; Chung EJ; Citrin DE; Wang Y; Hauer-Jensen M; Zhou D; Meng A
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):353-361. PubMed ID: 28479002
[TBL] [Abstract][Full Text] [Related]
12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
15. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
[TBL] [Abstract][Full Text] [Related]
16. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
17. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
20. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
